Results 51 to 60 of about 7,470 (208)
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang +2 more
wiley +1 more source
ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad +4 more
wiley +1 more source
Massive Atropine Eye Drop Ingestion Treated with High-Dose Physostigmine to Avoid Intubation
Case: A 34-year-old male presented after ingesting 150 mg of atropine. He had altered mental status, sinus tachycardia, dry mucosa, flushed skin, and hyperthermia.
Samuel J. Stellpflug +4 more
doaj
Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors [PDF]
Purpose: To determine the duration of antimuscarinic therapy for overactive bladder syndrome (OAB) appropriate for assessment of the efficacy of treatment, and to evaluate the possible predictive factors for response to therapy. Methods: All OAB patients
Sheng-Mou Hsiao +3 more
doaj +1 more source
Advancing Personalized Care for Neurogenic Bladder: The Case for Continent Urinary Diversion
ABSTRACT Introduction Neurogenic lower urinary tract dysfunction (NLUTD) with a poorly compliant bladder that is refractory to minimally invasive therapies (MIT) represents an “end‐stage” phenotype in which the principal objectives are durable upper urinary tract protection and restoration of continence with acceptable long‐term morbidity.
Francis A. Jefferson, Maude E. Carmel
wiley +1 more source
The antimuscarinic drug atropine caused a marked fall in plasma pepsinogen values of sheep with burdens of Ostertagia circumcincta and this response was greater in animals which had higher plasma pepsinogen values before administration of the drug.
Mostofa, M., McKellar, Quintin
core +4 more sources
We evaluated the efficacy and tolerability of Gosha-jinki-gan (GJG; 濟生腎氣丸 jì shēng shèn qì wán) in 30 cases of nocturia (夜尿 yè niào) unresponsive to α1-blockers or antimuscarinic drugs.
Hiroshi Yagi +5 more
doaj +1 more source
ABSTRACT Objectives Drug treatment for overactive bladder (OAB) is changing, with an increasing share of β3‐adrenoceptor agonists relative to anticholinergics, but it is not known how far this change has progressed in older people, who are most vulnerable to the risks of anticholinergics.
Toshikazu Koike +9 more
wiley +1 more source
Objective: To compare these managements focusing on the efficacy and safety to treat overactive bladder (OAB) in children through network meta-analysis (NMA). Methods: We searched PubMed, Embase, the Cochrane Library Central Register of Controlled Trials
Shi Qiu +11 more
doaj +1 more source
Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. [PDF]
PURPOSE:To describe the use of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark, Sweden, and the United Kingdom (UK). METHODS:We identified new users of darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium aged ...
Andrea V Margulis +13 more
doaj +1 more source

